You are here: Home » News-ANI » Health
Business Standard

Parkinson's disease may be diagnosed by testing caffeine level in blood

ANI  |  Washington DC 

A new research has found that the level in the blood may help in the diagnosis of

The were published on January 3, 2018, and stated the people suffering from have a significantly lower level of in their blood as compared to people not affected by the disease, even if the consumed amount of is same.

"Previous studies have shown a link between and a lower risk of developing disease, but we haven't known much about how metabolises within the people with the disease", said Shinji Saiki, MD, PhD, of the Juntendo University School of in Tokyo,

The study was conducted on 108 people who had had for an average of about six years and 31 people of the same age group who did not have the Their blood was tested for and for 11 the body makes as it metabolises They were also tested for mutations in genes that can affect metabolism.

According to David G Munoz, MD of the in Canada, who authored an accompanying editorial about the study, said the people with more severe stages of did not have lower levels of in their blood, suggesting the decrease only occured in the earliest stages of the

"If these can be confirmed, they would point to an easy test for early diagnosis of Parkinson's, possibly even before symptoms are appearing", Munoz said, adding, "This is important because is difficult to diagnose, especially at the early stages."

The coffee consumption for the groups was monitored to the same amount with an average equivalent of about two cups of coffee per day. However, the people with had lower and 11 by-product levels in their blood. The level was an average of 79 picomoles per 10 microlitres for people without disease, compared to 24 picomoles per 10 microlitres for people with the For one of the by-products, the level was below the amount that could be detected in more than 50 per cent of the people with

The researchers found that the test could be reliably used to identify people suffering from the disease, with a score of 0.98 where a score of 1 means that all cases are identified correctly, in statistical analysis.

In genetic analysis, they found that there were no differences in caffeine-related genes between the two groups.

Limitations of the study were that the people with severe were not included, hence jeopardising the ability to detect an association between severity and levels. Munoz also noted that all of the people with were taking medication and it's possible that these drugs could affect the metabolism of

The research was published in the online issue of Neurology, the medical journal of the

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, January 08 2018. 16:05 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU